Blog & News
ERNs start work March 1, 2017
Newly established European Reference Networks (ERNs) start their work March 1, 2017 24 thematic ERNs, gathering over 900 highly specialised healthcare units from 26 countries, will begin working together on a wide range of issues. Among them the ERN for…
Interest Group Developed Sarcoma Policy Checklist
On 8th of February 2017 a rare cancer policy debate at the European Parliament took place on how to improve the policy response to rare cancers, with a focus on sarcoma. Representatives from the European Commission, Member States, the European Parliament, industry…
eSurge 2016 Summary
On the 15th and 16th of November 2016, 50 surgeons from 13 different countries met in Institut Curie, Paris to attend the fifth edition of the esurge sarcoma surgery masterclass developed and directed by Dr Sylvie Bonvalot (Institut Curie) and Dr Alessandro…
Unesbulin in Advanced Leiomyosarcoma (SUNRISELMS)
Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) (SUNRISELMS) Agents: Unesbulin in combination with dacabazine Phase II/III Status Recruiting Sponsor PTC Therapeutics Further information: https://clinicaltrials.gov/ct2/show/NCT05269355 This study compares the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in patients…
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas (DOREMY) (2)
Agents: Radiotherapy Phase II Status Closed, active Sponsor The Netherlands Cancer Institute Further information: https://clinicaltrials.gov/ct2/show/NCT02106312 WHO is the trial for? Adult patients with confirmed Myxoid Liposarcoma (MLS) of the soft tissue without metastasis or with only a small number of…
Selinexor in Advanced Liposarcoma (SEAL)
Selinexor in Advanced Liposarcoma (SEAL) Agents: Selinexor Phase II/III Status Closed, active Sponsor Karyopharm Therapeutics Inc Further information: https://clinicaltrials.gov/ct2/show/NCT02606461 This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma (DDLS) WHO is…
Intrigue: DCC-2618 vs sunitinib in advanced GIST after treatment with imatinib
Agents: DCC-2618 (Ripretinib) vs. Sunitinib Phase III Status Closed for recruitment, active Sponsor Deciphera Pharmaceuticals LLC Further information: https://clinicaltrials.gov/ct2/show/NCT03673501 WHO is the trial for? Patients with confirmed advanced or metastatic GIST Patients must have progressed on imatinib or are…
TRC105 in combination with pazopanib vs. pazopanib alone in advanced angiosarcoma (TAPPAS)
This study evaluates the efficacy and safety of TRC105 in combination with pazopanib vs. pazopanib alone in advanced angiosarcomas. Trial name TAPPAS Agents TRC105 and pazopanib Phase III Status Terminated Sponsor Tracon Pharmaceuticals Inc. A randomized phase III trial of TRC105 and…